Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

vertex-headquarters

FDA approves Vertex’s Trikafta in new indication, now potentially covering 90% of cystic fibrosis patients

October 23, 2019 Research and Development, Sales and Marketing FDA, Trikafta, Vertex, cystic fibrosis, pharma

The FDA has granted marketing authorisation to Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), it …
News

New study shows Prozac no better than placebo in treating autism

October 23, 2019 Research and Development

A small study has found that the commonly prescribed medication for kids and teenagers with autism is no more effective …
News
opdivo_1_1

BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer

October 23, 2019 Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …
News
biogen_logo

Biogen aiming for Aducanumab to slow Alzheimer’s progression

October 23, 2019 Research and Development

US firm Biogen is hoping for approval to bring about a treatment that could slow the onset of Alzheimer’s disease. …
News
takeda_world

Takeda acquires investigational coeliac disease therapy

October 23, 2019 Research and Development

Takeda has acquired licensing for a first-in-class investigational coeliac disease therapy CNP-101/TAK-101. The Japanese pharma giant now has the rights …
News
shutterstock_159488225

Porton Biopharma signs potential $24m deal to push its intranasal anthrax vaccine into Phase 1 trials

October 22, 2019 Manufacturing and Production, Research and Development FDA, Porton Biopharma, anthrax, pharma

Porton Biopharma has signed a modification to its existing agreement with the US National Institute of Health’s National Institute of …
News
brexit-hintergrund_web

“No deal” Brexit and life sciences: What happens?

October 21, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Europe, UK, brexit, no deal, no-deal, pharma

Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite …
Feature
rocheshanghai

Roche’s Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma

October 21, 2019 Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
News

Medical cannabis: Growth by leaps and bounds

October 18, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Canopy Growth, medical cannabis, pharma

This article follows parts one and two of our trio of in-depth pieces focusing on the growing medical cannabis phenomenon. …
Feature
top_10_photo

Top Ten most popular articles on Pharmafile.com this week

October 18, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

It’s time for a rundown of the top 10 articles on PharmaFile this past week. The past seven days saw …
News

UCB’s bimekizumab meets primary and secondary endpoints, beating Janssen’s Stelara in chronic plaque psoriasis

October 17, 2019 Research and Development Stelara, UCB Pharma, bimekizumab, pharma, plaque psoriasis

UCB Pharma has announced new data from the first of three Phase 3 studies investigating the efficacy of its IL-17A …
News
ipsen-logo-big

Ipsen acquires Blueprint drug and moves further into ultra-rare disease

October 17, 2019 Research and Development

Ipsen has announced that through its subsidiary Clementia Pharmaceuticals, it has entered into an exclusive, worldwide license agreement for the …
News

Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer

October 17, 2019 Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma

In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …
News

AstraZeneca receives FDA Priority Review for breast cancer drug

October 17, 2019 Research and Development

AstraZeneca have announced that the US FDA has granted Priority Review for its experimental breast cancer treatment trastuzumab. The Prescription …
News
andrew_dickinson

Gilead appoints Andrew Dickinson as CFO

October 16, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Gilead Sciences have announced that Andrew Dickinson has been appointed as Chief Financial Officer (CFO) effective 1 November. Dickinson currently …
Appointment
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026